MANE Company Profile and Key Details

NYSE : MANE

Veradermics

$118.25

1.45+1.24%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Veradermics, Incorporated (MANE) stock surged +1.24%, trading at $118.25 on NYSE, up from the previous close of $116.80. The stock opened at $116.55, fluctuating between $116.55 and $121.10 in the recent session.

Stock Snapshot

116.8

Prev. Close

4.94B

Market Cap

116.55

Day Low

-37.65

P/E Ratio

-3.14053

EPS (TTM)

N/A

Cash Flow per Share

116.55

Open

41.78M

Number of Shares

121.0999

Day High

N/A

Free Float in %

N/A

Book Value

300.74K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	116.55	121.10	116.54	118.25	350.35K
Jul 07, 2026	123.99	125.20	116.56	116.80	384.8K
Jul 06, 2026	128.11	129.81	121.75	122.07	537K
Jul 02, 2026	128.04	130.86	122.88	129.74	563K
Jul 01, 2026	122.13	131.24	120.00	128.48	737.88K
Jun 30, 2026	120.00	126.76	120.00	122.94	608.75K
Jun 29, 2026	126.71	126.89	120.38	123.58	720.79K
Jun 26, 2026	117.64	128.24	117.00	126.89	4.03M
Jun 25, 2026	116.20	121.45	114.01	119.37	1M
Jun 24, 2026	104.38	118.70	102.87	117.29	1.03M
Jun 23, 2026	100.49	107.32	100.49	103.60	615.95K
Jun 22, 2026	96.03	106.00	95.93	102.79	877.84K
Jun 18, 2026	93.59	94.44	86.83	93.87	816.89K
Jun 17, 2026	91.16	95.20	89.30	91.87	414.68K
Jun 16, 2026	95.52	97.20	90.82	90.95	496.93K
Jun 15, 2026	96.74	97.83	94.97	96.27	294.93K
Jun 12, 2026	94.37	98.93	92.11	96.07	260.38K
Jun 11, 2026	93.68	98.64	93.25	94.40	201.99K
Jun 10, 2026	95.00	100.40	91.18	92.98	399.53K
Jun 09, 2026	91.33	97.19	91.33	95.91	489.29K

Contact Details

New Haven, CT 06513

United States

https://www.veradermics.com 228 372 3376

About Company

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.

Stock Peers

RCUS

0.01+0.03%

Arcus Biosciences, Inc.$30.26 AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 ANRO

0.39+1.52%

Alto Neuroscience, Inc.$26.09 BHVN

1.09+7.01%

Biohaven Ltd.$16.64 EVMN

-0.09-0.67%

Evommune, Inc.$13.25 DNA

-0.27-2.89%

Ginkgo Bioworks Holdings, Inc.$9.07 EBS

-0.15-1.81%

Emergent BioSolutions Inc.$8.14 NUVB

0.2+3.53%

Nuvation Bio Inc.$5.87 ANVS

0.07+3.65%

Annovis Bio, Inc.$1.99 ADCT

-0.07-5.19%

ADC Therapeutics S.A.$1.28

Company Overview

Veradermics, Incorporated (NYSE:MANE) closed at $118.25 USD, gaining $1.45 (1.24%) from the previous close of $116.80. The stock is currently mid-range between its 52-week high and low $32.00 and $131.24. With a market capitalization of about $4.94 billion, Veradermics, Incorporated is classified as a mid-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 661.07 thousand shares, volume is running light vs its 52-week average. Headquartered in New Haven, CT, Veradermics, Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Reid Waldman, the company employs approximately 21 people and listed since February 04, 2026. Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.06%, SMA50 -0.06%, SMA200 -0.06%). The stock’s 14-day RSI is 59.28 (neutral), while the ATR of 4.21 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -16.78% below its high and over 34.09% above its low. Average 10-day trading volume of 557.51 thousand shares is below the 3-month average of 659.80 thousand, indicating normal recent market interest.

Valuation Metrics

Veradermics, Incorporated trades at a P/E ratio of -76.71, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 11.4 reflecting a rich premium to book value. The P/FCF stands at -111.6, also above market averages. Compared to sector medians, Veradermics, Incorporated P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Veradermics, Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.62. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $182.00 to $75.00. The high target offers 53.91% upside. The low target suggests -36.58% downside. The mean target is $114.12. This offers -3.49% upside. Veradermics, Incorporated earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 107.12%. The prior quarter beat by -41.47%. Over the last six quarters, Apple has recorded several small beats. These include -10.31% in February 25, 2026.

Financial & Profitability Overview

Over the trailing twelve months, Veradermics has not generated any revenue.
On valuation metrics, Veradermics trades at a P/E of -76.71, P/S of 0.00 and P/B of 11.40. The current ratio is 59.12 and quick ratio is 59.12.

Price Forecast & Outlook

Our AI price prediction model suggests that Veradermics, Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 21.77%, with price expected at $143.99 by July 22, 2026, within a range of $137.86 to $150.75 3-Month Outlook: Projected rise of 72.21%, reaching $203.64 by October 06, 2026, with a range of $202.74 to $204.51. 1-Year Outlook: Projected gain of 180.67%, with price at $331.89 by July 08, 2027, within a range of $330.92 to $333.04.

Key Takeaways

currently trading near 52-week highs band. Valuation shows Veradermics, Incorporated trading at a premium to the broader market with a P/E of -76.71. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $114.12, suggesting -3.49% downside. Our AI forecast model points to short-term strength (21.77% over two weeks), a medium-term rise (72.21% over three months), and a longer-term gain (180.67% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Veradermics, Incorporated (MANE) stock price?

Veradermics, Incorporated (NYSE: MANE) stock price is $118.25 in the last trading session. During the trading session, MANE stock reached the peak price of $121.10 while $116.55 was the lowest point it dropped to. The percentage change in MANE stock occurred in the recent session was 1.24% while the dollar amount for the price change in MANE stock was $1.45.

MANE's industry and sector of operation?

The NYSE listed MANE is part of Biotechnology industry that operates in the broader Healthcare sector. Veradermics, Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MANE?

No Data

How MANE did perform over past 52-week?

MANE's closing price is 269.53% higher than its 52-week low of $32.00 where as its distance from 52-week high of $131.24 is -9.9%.

How many employees does MANE have?

Number of MANE employees currently stands at 21.

Link for MANE official website?

Official Website of MANE is: https://www.veradermics.com

How do I contact MANE?

MANE could be contacted at phone 228 372 3376 and can also be accessed through its website. MANE operates from 470 James Street, New Haven, CT 06513, United States.

How many shares of MANE are traded daily?

MANE stock volume for the day was 300.74K shares. The average number of MANE shares traded daily for last 3 months was 661.07K.

What is the market cap of MANE currently?

The market value of MANE currently stands at $4.94B with its latest stock price at $118.25 and 41.78M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	21
Beta	0.77
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MANE Company Profile and Key Details

Veradermics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics